Misyo (Methadone Hydrochloride)

Methadone hydrochloride binds to μ‑opioid receptors as a full agonist, producing analgesic effects and suppressing withdrawal by mimicking endogenous opioids. Its long half‑life maintains steady plasma levels, and its NMDA‑receptor antagonism may help reduce tolerance and neuropathic pain.

The appropriate dose of Misyo is individualized and must be determined by a qualified prescriber based on the patient’s clinical condition, prior opioid exposure, and response to therapy. Dosage adjustments are made according to therapeutic goals and safety monitoring.

Methadone can be used during pregnancy when the benefits outweigh potential risks, as it reduces the chance of illicit opioid use and associated complications. However, it crosses the placenta and is excreted in breast milk, so clinicians should assess each case carefully and monitor the infant for respiratory depression.

To order Misyo, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

The primary alternative for opioid dependence is buprenorphine, a partial μ‑opioid agonist with a ceiling effect on respiratory depression. Methadone, a full agonist, offers more flexible dosing for severe pain but carries a higher risk of respiratory depression and cardiac QT prolongation, requiring closer monitoring.

Misyo should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiry date indicated on the label.

Misyo is administered orally, typically as a tablet or solution, and should be taken exactly as prescribed. Swallow tablets whole with water; if a liquid form is supplied, measure the dose with a calibrated device. Do not crush or chew extended‑release formulations unless directed by a healthcare professional.

The most serious risks include respiratory depression, especially during dose initiation or when combined with other depressants, and cardiac arrhythmias due to QT interval prolongation. Patients should be monitored for signs of severe sedation, shallow breathing, or irregular heart rhythms, and any concerning symptoms should prompt immediate medical attention.

Misyo is contraindicated in individuals with known hypersensitivity to methadone, those with severe respiratory depression, uncontrolled asthma, or significant cardiac arrhythmias such as prolonged QT syndrome. Caution is also advised for patients with severe hepatic impairment or those taking interacting medications that could elevate methadone levels.